Methods of Detection of Measurable Residual Disease in AML
1Department of Laboratory Medicine, University of Washington, 825 Eastlake Ave E, Rm G7-800, Seattle, WA, 98109, USA.
Abstract:
The presence of measurable ("minimal") residual disease (MRD) after induction and/or consolidation chemotherapy is a significant risk factor for relapse in patients with acute myeloid leukemia (AML). In recognition of the clinical significance of AML MRD, the European LeukemiaNet (ELN) recently recommended the establishment of CR-MRDNegative as a separate category of treatment response. This recommendation represents a major milestone in the integration of AML MRD testing in standard clinical practice. This review article summarizes the methodologies employed in AML MRD detection and their application in clinical studies that provide evidence supporting the clinical utility of AML MRD testing. Future MRD evaluations in AML likely will require an integrated approach combining multi-parameter flow cytometry and high-sensitivity molecular techniques applied to time points during and after completion of therapy in order to provide the most accurate and comprehensive assessment of treatment response.
Insights
Minimal residual disease (MRD) detection after acute myeloid leukemia (AML) treatment is crucial for predicting relapse. European LeukemiaNet (ELN) now recommends MRD-negative status as a distinct treatment response category.
Area of Science:
- Hematology
- Oncology
- Clinical Pathology
Background:
- Minimal residual disease (MRD) post-chemotherapy is a key predictor of relapse in acute myeloid leukemia (AML).
- The European LeukemiaNet (ELN) has recognized the clinical importance of MRD by recommending MRD-negative complete remission (CR-MRDNegative) as a distinct treatment response category.
- This integration of MRD testing into clinical practice marks a significant advancement in AML management.
Purpose of the Study:
- To review methodologies for detecting MRD in AML.
- To summarize clinical studies demonstrating the utility of MRD testing in AML.
- To highlight the evolving landscape of MRD assessment in AML.
Main Methods:
- Review of current AML MRD detection methodologies, including flow cytometry and molecular techniques.
- Analysis of clinical studies evaluating the prognostic value of MRD.
- Discussion of integrated approaches for comprehensive MRD assessment.
Main Results:
- MRD presence post-induction/consolidation chemotherapy is a significant risk factor for AML relapse.
- ELN's recommendation for CR-MRDNegative status signifies the clinical utility of MRD testing.
- Evidence supports the integration of MRD testing into standard clinical practice.
Conclusions:
- Accurate MRD assessment is vital for predicting relapse risk in AML patients.
- Future AML MRD evaluations necessitate an integrated approach combining flow cytometry and molecular methods.
- Comprehensive MRD assessment across multiple time points during and after therapy is essential for precise treatment response evaluation.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
05:24Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021